Avance BullishAs a result to the Covid-19 the LPG market fell way below their "fair-value", which is strongly indicated in the Price/ Earnings-value around 3.1-5.1.
The stock repeatedly shows a bullish RSI in the field between 50-75.
Besides the MacD indicator showing a strong momentum to proceed the trend
I personnel believe that the stock will try entering the same pattern as it did in the strong up-trend before the Covid-19 pandemic.
This would indicate a fair-value (relative to the value before the pandemic) around 70 NOK
BW LPG shifted to positive long-term trendBW LPG shifted to positive long term-trend.
The stock has proceeds following a positive trend with positive indicaters.
The stock shows a continued momentum to proceed upwards and follow the trend.
ACC_MERSI play: Long Above 50 RSI. See line.
Twin 0.618 retracement and twice strong support on hourly 200 MA .
Could see further movement up. But not long until support is retested on moving average or diagonal support line from September and RSI sees break from 50.
Anyone interested in buying VOW? Best time to enter!Descending channel breakout/b] , retest into local support , resumption??. This might be the best time to enter VOW for a swing trade perspective and a long term perspective.
SHLF looking bullish, looking for entrySo very brief analysis of SHLF, as it is definitively giving signs of life.
We have just arrived at major resistance that previously acted as support for a long time. So expecting a retrace from here, before even looking for a buying opportunity.
Furthermore a gap was left behind at 2.48 yesterday that will likely get filled. And we are inside the daily cloud --> consolidation.
I see 3 possible scenarios:
GREEN, Very bullish:
We break resistance and out of the cloud, we retest and continue up. Buy on the retest.
ORANGE, "normal":
We fill the gap, retest the bottom of the D cloud and find support in the cloud and on the 0.5 or 0.618 fib.
RED, "bottom formation":
We go back down looking for a bottom, possibly forming a double bottom or another bottom formation.
In conclusion; wait to see where SHLF starts to find support, or if it breaks up, look for the retest and buy.
$NEL Hydrogen testing key level 20NOK on Green New Deal hopes$NEL Hydrogen clearly will benefit from a Biden presidency! If it can establish trading above 20 NOK, the stage looks set for a strong pre christmas rally.
SATS swinglooking for a good drop below monthly vwap and reversal signal before entering. SATS is currently closing it's gyms because of covid-19. The company says it has good liquidity and will most likely survive the new lockdown. Looking forward to a good potential swing.
Learning TAHi,
Follow me along, while I'm trying to learn TA indicators.
This does not hold any relevancy to current market and is for learning purposes only.
x
LS
NEL on Oslo MarketForming Symmetrical Triangle: let see... Q3 on 5th November will be released too.
it might inevitably breach the upper trendline for a breakout and uptrend on rising or alternatively breach the lower trendline for a breakdown and downtrend with falling prices... Let's see :)
SoftOx Infection remover - US Department of Defense (DoD) grantSoftOx, today announced the US Department of Defense (DoD) awarded SoftOx $1.977 million (USD) for research and development of the SoftOx Infection remover (Biofilm Eradicator).
Oslo 03.11.2020
The project is a research and development collaboration between SoftOx Solutions AS and leading US and European wound care clinics, focusing on chronic wounds and biofilm infections. The project represents an innovative treatment principle in how to prevent and treat biofilm infections in wounds. The grant will contribute to perform clinical investigations to evaluate the SoftOx technology in humans with serious non-healing wounds.
The award was issued on behalf of the Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) a biomedical technology consortium that collaborates under a transaction agreement (OTA) with the US Army Medical Research and Development Command (USAMRDC). The award issued is entitled “Clinical Development of a New Antimicrobial Agent to Treat and Prevent Biofilm Formation in Wounds”. SoftOx considers it a great honor that one of the world’s leading research organizations supports the development and the technology of SoftOx by issuing the award.
About SoftOx Solutions
SoftOx Solutions AS (SoftOx, listed at Oslo Stock Exchange Merkur Market) is a Norwegian MedTech company based in Oslo with the aim to contribute to fight major threats to human health, namely; the Emergence of Antimicrobial Resistance (AMR), Biofilm Infections in Chronic Wounds and Spread of viruses. For more information about SoftOx please visit www.soft-ox.com
About Medical Technology Enterprise Consortium
MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command. To find out more about MTEC, visit www.mtec-sc.org.
Possible break of trend line15 day EMA, indicates a test of a new high. Potentiel breakout from trendline, could cause new all time high
CrayonTwin 0.382 retracement coinciding with a channel support line.
Crayon has a habit of extending 1.618 of previous run before a correction (wave 3 = x1.618 wave 1), ranging back to 2018. If these extensions were applied to Wave 3 and to Wave 1→ peak Wave 3 and with a target being the channel resistance it would lead to a target somewhere within the red bubble in early 2021.
Wave 1 and Wave 3 have an almost identical % rise (128.2% and 126.9% respectively). If these % gains were applied to wave 5 at a place where it would coincide with the resistance line of the channel it would also lead to that target being met somewhere in early 2021 within the red bubble. However there is no guarantee there will be a third identical % rise and the prioritized target is the channel resistance line.
Photocure Self Explanatory.
Target flexible (Calculated Wave 1 = Wave 5). Prioritize channel resistance.
Photocure Long (retracement first)The whole stock market is experiencing the same type of "crack" as it did back in Feb/March, now being fueled by a Covid second wave and uncertainty around the US elections. Photocure's RSI is approaching its year low levels in March. The down period in March lasted for about 1 month. The length of this down period will be more uncertain depending on the outcome of the election. Regardless, I see Photocure retracing to between 71 and no more than 57NOK (which would equal a retracement of 0.786, same as in feb/march) before turning around and going to new heights. Currently the company's market valuation is around 2bn NOK. A price target of between 180-220 NOK in May 2021 would give it a market value of 5-6bn NOK which is not unlikely at all. 50 day MA will most likely cross down the 250 MA at first. When it crosses back up, we'll know this company will go to new heights.
Softox promising consolidation above 50 SMALook for the stock punching through 200 SMA on good volume
Crayon Long - Fibonacci x Elliot WaveCrayon looks to have entered a bullish pattern closely resembling the elliot wave theory. Support and resistance levels fit well with what is expected to see in a fibonacci and elliot wave combination. RSI shows the stock has not been this underbought since March. Support at 105 and price target is set to about 184 in January. If Crayon falls through the 105 support line, next support is expected to appear at 94 NOK.
BWLPGConfluence between rising wedge and resistance at a 47.00. Strong reject.
Could retest rising support line before next breakout attempted.
Long at breakthrough of resistance at 47.
#SoftOx closer to a possible breakthrough against #covid19The Danish Medicines Agency has given its recommendation for further development of the SoftOx inhalation solution for the treatment of respiratory infections, including COVID-19.
The SoftOx Inhalation Project aims to develop an inhalation solution for the treatment of respiratory infections. This has the potential to be a breakthrough in the treatment of respiratory infections including Covid-19 infections. Following a scientific advisory meeting with the Danish Medicines Agency, a favorable development path has been suggested to be able to start testing in humans as soon as possible.
- It is now expected that the first studies in humans can start as early as the second quarter of 2021. SoftOx will therefore immediately start preparations to provide the necessary documentation that involves further safety studies in animal models, says Geir Almås, CEO of SoftOx Solutions.
- The need for new solutions treating respiratory tract infections is significant, this is a market which with conservative estimates for the EU and the US is approximately 12 billion USD. The number can probably be doubled looking in a global perspective, continue Almås.
This technology is unique, it is simple, exceptionally effective and does not trigger resistance. The effect is also independent of possible new mutated variants, as recently reported for the Corona virus.
- My team and I believe that we are facing a breakthrough in the treatment of difficult infections, both viral and bacterial. We have tested SoftOx solutions in the respiratory tract and we see that this can be an important treatment principle that can help fight the ongoing pandemic and future epidemics and pandemics ", says Professor of Microbiology and trial leader Thomas Bjarnsholt at the University of Copenhagen.
For more information contact:
Professor Thomas Bjarnsholt; tbjarnsholt@sund.ku.dk +45 206 59 888
CEO Geir Almås; geir.almaas@soft-ox.com +47 977 59 071
Professor Thomas Bjarnsholt is a member of the company's Scientific Advisory Board and has 20.000 stock options in SoftOx Solutions.
ArcticZymes $AZT Q3 2020 reportHighlights for Q3 2020
• Annual group sales exceed 100 MNOK for the first time
• Gross profit for the Group improved 65% to NOK 26.0 million (Q3 2019: NOK 15.7 million)
• ArcticZymes had Q3 sales of NOK 19.5 million growing by 63% (Q3 2019: NOK 12.0 million)
• Biotec BetaGlucans had Q3 sales of NOK 11.2 million growing by 7% (Q3 2019: NOK 10.5 million)
• Upsides relating to COVID-19 pandemic is estimated at NOK 4 million for ArcticZymes and NOK 1.25 million for consumer health
• The Group delivered positive EBITDA with NOK 10.1 million (Q3 2019: NOK 0.8 million)
• Cash-flow for Q3 was positive NOK 13.6 million (Q3 2019: NOK 0.7 million) giving a cash balance of NOK 69.7 million (Q3 2019: NOK 22.1 million)
